The
Briefing.

HHS issues an interim policy: no action against licensed compounding of six peptides

The Department of Health and Human Services has issued an interim enforcement-discretion policy, STAT News reported on October 28. HHS said it will not act against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, TB-500, epitalon, MOTS-c, KPV and Semax. These are the six backed by an FDA advisory committee in July. Earlier this month the policy went to the White House budget office for review, with its text and peptide list not yet public; now both are out.

What it means for a reader: this is a statement about enforcement. HHS is saying it will hold back from acting against certain licensed compounders for these six compounds while the policy stands. The word interim matters too. This is not presented as a final rule, so it can still change.

What it does not mean: HHS itself said the policy does not grant FDA approval and does not show that any of the six peptides are safe or effective. The evidence behind them is the same as it was last week, and for most of them human data is limited. The policy also covers licensed pharmacies, federal facilities and licensed physicians, not anyone else.

Reaction is split. A pharmacy safety group called it illegal compounding. The Alliance for Pharmacy Compounding welcomed the policy but said dispensing may take time to start. For what each peptide is and what the evidence actually shows, see the individual dossier pages, including TB-500 at jointhedailystack.com/peptides/tb-500/.

Source: STAT News

Retatrutide beat Ozempic on blood sugar and weight in a Phase 3 diabetes trial, Lilly says

Eli Lilly released topline results from TRANSCEND-T2D-2, a Phase 3 trial in people with type 2 diabetes that compared retatrutide head-to-head with Ozempic at its highest approved dose. At 80 weeks, both retatrutide doses tested lowered A1C, a measure of average blood sugar, by 2.2%, compared with 1.8% for Ozempic. Average weight loss was 20-21% with retatrutide versus 9% with Ozempic. Lilly says it plans to file retatrutide for FDA approval in the first quarter of 2027.

What it means: retatrutide targets three hormone pathways (GLP-1, GIP and glucagon), while semaglutide, the drug in Ozempic, targets one. This is a direct comparison in a large, late-stage trial, which is stronger evidence than comparing numbers across separate studies. The weight gap in particular is large.

What it does not mean: these are topline results announced in a company press release, not a full peer-reviewed paper. The release summary provided here does not include side-effect rates, which matter a lot for a drug thought to be harder on the stomach than single-target options. Retatrutide remains investigational and is not FDA-approved; a filing is a request for review, not a decision. More on the compound at jointhedailystack.com/peptides/retatrutide/.

Source: Eli Lilly (press release); also covered by BioSpace and AJMC

Semaglutide cut weight and fat in Asian adults with lower BMIs

A 44-week randomized trial of 242 Asian adults found that weekly semaglutide reduced body weight by 12.1%, compared with 2.2% on placebo, Endocrinology Advisor reported. Participants met region-specific criteria for overweight or obesity, with a BMI of 24 to under 30, a lower range than the cutoffs often used elsewhere. In a subgroup scanned with DXA, which measures body composition, total fat mass fell 27.4% versus 6.8% on placebo. Waist circumference, visceral fat (the fat around the organs) and blood sugar control also improved.

What it means: much of the big semaglutide evidence comes from people with higher BMIs. This trial tests the drug in a group whose weight would not always count as obesity under general cutoffs, but who met their region's criteria. The fat-mass and visceral-fat results suggest the weight lost was largely fat, at least in the scanned subgroup.

What it does not mean: this is a mid-sized trial over 44 weeks, so it does not tell us about longer-term results or what happens after stopping. The report summarised here does not detail side effects. And it applies to people who met these specific criteria, not to anyone with a BMI in that range. The semaglutide dossier is at jointhedailystack.com/peptides/semaglutide/.

Source: Endocrinology Advisor

In focus: no, retatrutide is not an approved drug yet

The myth: retatrutide is already an approved medicine, just a newer, stronger cousin of semaglutide and tirzepatide. With headlines like this week's, it is easy to see why people assume so.

The fact: retatrutide is investigational. It is not FDA-approved, and it is still in late-stage clinical trials. Lilly has said it plans to file for FDA approval in the first quarter of 2027. Filing starts a review; it does not guarantee an approval, and the review weighs the full trial data on benefit, safety and manufacturing.

Why the excitement is real, though. Retatrutide acts on three hormone receptors at once: GLP-1, GIP and glucagon. The first two reduce appetite and slow digestion, much as tirzepatide does. The glucagon effect appears to raise energy use and help the liver burn fat, which is thought to explain the larger results. In a 48-week Phase 2 trial, the highest dose produced about 24% average weight loss, and larger Phase 3 trials are under way. It is also being studied for fatty liver.

The trade-off that tends to get left out: the same mechanism that may boost results is also thought to explain more noticeable side effects. The stomach pattern resembles tirzepatide's but is more pronounced, and some people report an odd tingling or sensitivity of the skin. Persistent vomiting, severe abdominal pain or skin symptoms that do not settle need medical attention, and it is not for anyone with a history of medullary thyroid cancer or MEN2.

The bottom line: promising trial data and approval are two different things. Until a regulator has reviewed the full picture, retatrutide remains an experimental drug. The dossier at jointhedailystack.com/peptides/retatrutide/ keeps the details in one place.